ArticleScientific reports2020
Quantification of the content of cannabinol in commercially available e-liquids and studies on their thermal and photo-stability.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.Pharmaceutics · 2026Review
- Exploring the therapeutic potential of cannabidiol in soft tissue wound healing: Delivery strategies and anti-inflammatory pathways.Acta pharmaceutica Sinica. B · 2026Review
- Not what it seems: analytical validation and label accuracy of commercial CBD oils using HPTLC.Journal of cannabis research · 2026Article
- Formulation and Functional Characterization of a Cannabidiol-Loaded Nanoemulsion in Canine Mammary Carcinoma Cells.Pharmaceutics · 2025Article
- The Potential of Cannabidiol for Treating Canine Atopic Dermatitis.Veterinary sciences · 2025Review
- Discovering the Potential of Cannabidiol for Cosmeceutical Development at the Cellular Level.Pharmaceuticals (Basel, Switzerland) · 2025Article
- An Unexpected Activity of a Minor Cannabinoid: Cannabicyclol (CBL) Is a Potent Positive Allosteric Modulator of Serotonin 5-HTJournal of natural products · 2025Article
- Understanding the Potential of CBD for Health Benefits: An Overview.Current drug discovery technologies · 2025Review
- Is nitrogen-modified atmosphere packaging a tool for retention of volatile terpenes and cannabinoids in stored Cannabis sativa inflorescence?Journal of cannabis research · 2024Article
- Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials.Child and adolescent psychiatry and mental health · 2024Review
- A multi-market comparison of composition, formulation, and label content of CBD e-liquids.iScience · 2024Article
- Improved quality of life and pain relief in mature horses with osteoarthritis after oral transmucosal cannabidiol oil administration as part of an analgesic regimen.Frontiers in veterinary science · 2024Article
- Cannabidiol usage, efficacy, and side effects: analyzing the impact of health conditions, medications, and cannabis use in a cross-sectional online pilot study.Frontiers in psychiatry · 2024Article
- Current Challenges and Opportunities for Improved Cannabidiol Solubility.International journal of molecular sciences · 2023Article
- A comparison of advertised versus actual cannabidiol (CBD) content of oils, aqueous tinctures, e-liquids and drinks purchased in the UK.Journal of cannabis research · 2023Article
- CBD hydroxyquinone photo-isomerises to a highly reactive intermediate.Scientific reports · 2023Article
- Cannabidiol-Loaded Nanostructured Lipid Carriers (NLCs) for Dermal Delivery: Enhancement of Photostability, Cell Viability, and Anti-Inflammatory Activity.Pharmaceutics · 2023Article
- Evaluation of an Oral Supplemental Cannabidiol Product for Acceptability and Performance in Mature Horses.Animals : an open access journal from MDPI · 2023Article
- On offer to Ontario consumers three years after legalization: A profile of cannabis products, cannabinoid content, plant type, and prices.Frontiers in psychiatry · 2023Article
- Characterizing the degradation of cannabidiol in an e-liquid formulation.Scientific reports · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabidiol (CBD) has become a buzzword in many products that have bloomed on the market. The scientific community and some authorities have recently raised concerns on the quality of these products. In particular, the discrepancy between the labelled and the real content of cannabidiol in liquids for e-cigarettes seems to be emerging as a major issue. Furthermore, to-date no studies have been carried out on the chemical stability upon storage of these type of products. The aim of this work was to investigate the accuracy in labelling of thirteen commercially e-liquids containing CBD and the effects of different storage conditions on their quality. The results showed that only 38% of samples were labelled within a ±10% variance from their labels. Stability tests showed a maximum degradation of CBD when samples were stored at 37 °C for 30 days with average values up to 20%. The effect of light was lower but still significant with averages values up to 15% degradation after 30 days. In conclusion, we believe that health authorities should regulate and control this market more stringently to protect customers and their health. Furthermore, our stability tests have shown that if clear indications are provided on the best storage conditions, the quality of these products can be mostly preserved.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.